IDEAYA Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
IDEAYA Biosciences, Inc. (IDYA) filed a Current Report on Form 8-K on August 4, 2026. The filing announces the financial results for the second quarter ended June 30, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that results were announced and directs readers to the attached press release (Exhibit 99.1) for detailed financial data.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the press release furnished as Exhibit 99.1 for comparative analysis.
Guidance, Outlook, and Risks
The filing does not include specific guidance, outlook, management commentary, or risk factors within the body of the 8-K. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless expressly stated.
Key Facts for Investor Verification
- Verify the specific revenue and net loss figures in the press release (Exhibit 99.1) attached to this filing.
- Confirm the company's cash position and runway as detailed in the full financial results.
- Review the press release for any updates on clinical trial progress or regulatory milestones for the quarter ended June 30, 2026.
- Note that the financial data in this 8-K is not incorporated by reference into other SEC filings unless explicitly stated.